ZIA CP005782-10070 (ZIA) | |||
---|---|---|---|
Title | Studies of Genetic Predictors of Therapeutic Response | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | O'Brien, Thomas | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $35,409 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) Interferon (5.0%) |
Liver Cancer (100.0%) | ||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Chemoprevention |
|||
Abstract | |||
"We study genetic factors that predict therapeutic response to treatment of hepatitis C virus in participants enrolled in HALT-C and in other cohorts. The HALT-C trial was designed to evaluate the safety and efficacy of long-term PEG-interferon-alfa for treatment of chronic hepatitis C in patients who did not respond to previous interferon therapy and who have evidence of hepatic fibrosis by biopsy. I am collaborating with the HALT-C investigators to examine potential genetic predictors of response to treatment and fibrosis among HALT-C participants. We make use of data and specimens that were collected from patients with chronic hepatitis C during these clinical trials, which entailed treatment with pegylated interferon plus ribavirin. We compare host genetic polymorphisms in non-responders to participants who responded to anti-viral treatment. This is a human population-based study in a clinical setting. This research has a molecular component in that DNA specimens are used to investigate gene markers that may be associated with treatment response. This study aims to detect genetic markers that make patients more likely to respond to anti-viral treatment and, therefore, less likely to develop hepatocellular carcinoma. " |